- Home
- GTY vs XERS Comparison
GTY vs XERS Comparison
Compare GTY & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GTY | XERS |
|---|---|---|
| Founded | 1955 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GTY | XERS |
|---|---|---|
| Price | $28.39 | $16.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $33.86 | $17.29 |
| AVG Volume (30 Days) | 490.7K | ★ 3.1M |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.97% | N/A |
| EPS Growth | 8.00 | ★ 100.00 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $221,727,000.00 | $49,590,000.00 |
| Revenue This Year | $8.60 | $37.58 |
| Revenue Next Year | $10.70 | $31.16 |
| P/E Ratio | $24.39 | ★ N/A |
| Revenue Growth | 9.02 | ★ 142.67 |
| 52 Week Low | $27.08 | $5.25 |
| 52 Week High | $36.83 | $16.11 |
Technical Indicators
Market Signals| Indicator | GTY | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 84.73 |
| Support Level | $27.30 | $5.90 |
| Resistance Level | $28.75 | N/A |
| Average True Range (ATR) | 0.52 | 0.67 |
| MACD | 0.14 | 0.59 |
| Stochastic Oscillator | 47.93 | 96.36 |
Price Performance
Historical ComparisonAbout GTY Getty Realty Corporation
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.